Immunogenicity of a booster vaccination against tick-borne encephalitis

  • Lucija Beškovnik Lucija Beskovnik, M.D., National Institute of Public Health, Regional Unit Celje, Ipavceva 18, SI-3000 Celje, Slovenia
  • Tatjana Frelih Tatjana Frelih, M.D., National Institute of Public Health, Trubarjeva 2, SI-1000 Ljubljana, Slovenia
  • Tatjana Avšič Županc Prof. Tatjana Avšič Županc, B.Sc. Ph.D., Institute of Microbiology and Immunology, University of Ljubljana, Faculty of Medicine, Zaloška 4, SI-1000 Ljubljana, Slovenia
  • Miša Korva Miša Korva, B.Sc. Ph.D., Institute of Microbiology and Immunology, University of Ljubljana, Faculty of Medicine, Zaloška 4, SI-1000 Ljubljana, Slovenia
  • Alenka Trop Skaza Alenka Trop Skaza, M.D. Ph.D.,National Institute of Public Health, Regional Unit Celje, Ipavceva 18, SI-3000 Celje, Slovenia
DOI: https://doi.org/10.6016/ZdravVestn.1487
Keywords: tick-borne encephalitis – TBE, epidemiology, vaccination, serological response, flavivirus.

Abstract

Abstract

Background: Tick-borne encephalitis is endemic in Slovenia, but still less than 10 % of people are regularly vaccinated. The proportion of vaccinated individuals was significantly influenced by obligatory vaccination for all Slovenian military conscripts between 1993 and 2003.

Methods: Our study includes 73 men from the Celje region, who were vaccinated with three doses of vaccine against tick-borne meningoencephalitis FSME-Immun® (Baxter), but afterwards they stopped the vaccination for a period of 8 to 16 years. Participating men were serologically tested before and after the first booster dose. We used the enzyme immunoassay Enzygnost®.

Results: The result of the analysis was, that with most of the participants the value of titer of antibodies before receiving revaccination was protective (n=67; 91,8 %), while after receiving a booster dose, the protective value was exceeded for all participants who have submitted a second blood sample (n=69; 94,5 %). Geometric mean concentration before the booster dose was 56 U/ml and 314 U/ml after the booster dose.

Conclusions: Our study confirmed the long-term protection after primary vaccination with three doses against tick-borne encephalitis with men younger than 50 years, by using enzyme immunoassay. The results support the careful consideration of currently recommended revaccination interval.

Downloads

Download data is not yet available.

Author Biography

Lucija Beškovnik, Lucija Beskovnik, M.D., National Institute of Public Health, Regional Unit Celje, Ipavceva 18, SI-3000 Celje, Slovenia

Avtor za dopisovanje: Lucija Beskovnik, dr.med., Nacionalni inštitut za javno zdravje, Območna enota Celje, Ipavčeva 18, SI-3000 Celje, Slovenija, Tel: +00386 42 51 205 ali 031 378 349 Fax: +003863 42 51 115, email: lucija.beskovnik@nijz.si

References

Kraigher A, Sočan M, Klavs I, Frelih T, Grilc E, Grgič Vitek M, et al. Epidemiological surveillance of infectious diseases in Slovenia in 2014. Ljubljana: National Institute of Public Health; 2015.

Heinz FX, Stiasny K, Holzmann H, Kundi M, Sixl W, Wenk M, et al. Emergence of tick-borne encephalitis in new endemic areas in Austria: 42 years of surveillance. Euro Surveill. 2015; 20 (13): 9–16.

Amato-Gauci A, Zeller H. Tick-borne encephalitis joins the diseases under surveillance in the European Union. Euro Surveill. 2012; 17 (42): 1–2.

Loew-Baselli A, Konior R, Pavlova BG, Fritsch S, Poellabauer E, Maritsch F, et al.; FSME-IMMUN study group. Safety and immunogenicity of the modifed adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies. Vaccine. 2006; 24: 5256–63.

Pollabauer EM, Pavlova BG, Loew-Baselli A, Fritsch S, Prymula R, Angermayr R, et al. Comparison of immunogenicity and safety between two paediatric TBE vaccines. Vaccine. 2010; 28 (29): 4680–5.

Loew-Baselli A, Poellabauer EM, Pavlova BG, Fritsch S, Firth C, Petermann R, et al. Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme. Vaccine. 2011; 29 (43): 7307–19.

Prymula R, Pöllabauer EM, Pavlova BG, Löw-Baselli A, Fritsch S, Angermayr R, et al. Antibody persistence afer two vaccinations with either FSME-IMMUN® Junior or ENCEPUR® Children followed by third vaccination with FSME-IMMUN® Junior. Hum Vaccin Immunother. 2012; 8 (6): 736–42.

Demicheli V, Debalini MG, Rivetti A. Vaccines for preventing tick-borne encephalitis. Cochrane Database Syst Rev. 2009;(1):CD000977.

Heinz F, Holtzmann H, Essl A, Kundt M. Analysis of the efciency of tick-borne encephalitis vaccination in the population in the natural foci of Austria. Vopr Virusol. 2008; 53 (2): 19–27.

Kunze U, Böhm G. Tick-borne encephalitis (TBE) and TBE-vaccination in Austria: Update 2014. Wien Med Wochenschr. 2015; 165 (13–14): 290–5.

Institute of Public Health of the Republic of Slovenia. Center for Infectious Diseases and Environmental Risks. Department of the vaccination program. Instructions for vaccination against TBE for doctors who vaccinate.

Grgic-Vitek M, Klavs I. Low coverage and predictors of vaccination uptake against tick-borne encephalitis in Slovenia. Eur J Public Health. 2012; 22 (2): 182–6.

Schosser R, Bartel J, Enzersberger O, Chiba P, Kaiser R, Mansmann U, et al. Comparison of two TBE IgG antibody ELISA tests (Enzygnost® And Immunozym®) versus a neutralization assay with respect to seropositivity thresholds. 10th International Jena Symposium on Tick-Borne Diseases; 2009; Weimar, Germany.

Weissbach FH, Hirsch HH. Comparison of Two Commercial Tick-Borne Encephalitis Virus IgG Enzyme-Linked Immunosorbent Assays. Clin Vaccine Immunol. 2015; 22 (7): 754–60.

World Health Organization. Vaccines against tick-borne encephalitis: WHO position paper. Wkly Epidemiol Rec. 2011; 86 (24): 241–56.

Wang D, Zheng Y, Kang X, Zhang X, Hao H, Chen W, et al. A multiplex ELISA-based protein array for screening diagnostic antigens and diagnosis of Flaviviridae infection. Eur J Clin Microbiol Infect Dis. 2015; 34 (7): 1327–36.

CDC. General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2011; 60 (No. RR-2): 1–60.

Bössenecker W. Tick-borne encephalitis: infection mechanisms, clinical picture and vaccination options. MMW Fortschr Med. 2007; 149 (5): 29–33.

Schöndorf I, Schönfeld C, Nicolay U, Zent O, Banzhoff A. Response to tick-borne encephalitis (TBE) booster vaccination afer prolonged time intervals to primary immunization with the rapid schedule. Int J Med Microbiol. 2006; 296 (40): 208–12.

Schondorf I, Beran J, Cizkova D, Lesna V, Banzhoff A, Zent O. Tick–borne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule. Vaccine. 2007; 25: 1470–5.

Wittermann C, Schondorf I, Gniel D. Antibody response following administration of two pediatric tick–borne encephalitis vaccines using two different vaccination schedules. Vaccine. 2009; 27: 1661–6.

Wittermann C, Izu A, Petri E, Gniel D, Fragapane E. Five year follow-up afer primary vaccination against tick-borne encephalitis in children. Vaccine. 2015; 33 (15): 1824–9.

Paulke-Korinek M, Rendi-Wagner P, Kundi M, Laaber B, Wiedermann U, Kollaritsch H. Booster vaccinations against tick-borne encephalitis: 6 years follow-up indicates long-term protection. Vaccine. 2009; 27 (50): 7027–30.

Beran J, Xie F, Zent O. Five year follow-up afer a frst booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates long-term antibody persistence and safety. Vaccine. 2014; 32 (34): 4275–80.

Askling HH, Vene S, Rombo L, Lindquist L. Immunogenicity of delayed TBE-vaccine booster. Vaccine. 2012; 30 (3): 499–502.

Kunz C. TBE vaccination and the Austrian experience. Vaccine. 2003; 21 (1): 50–5.

Zavadska D, Anca I, André F, Bakir M, Chlibek R, Cižman M, et al. Recommendations for tick-borne encephalitis vaccination from the Central European Vaccination Awareness Group (CEVAG). Hum Vaccin Immunother. 2013; 9 (2): 362–74.

Kunzeand U, ISW TBE. Tick-borne encephalitis as a notifable disease–Status quo and the way forward. Report of the 17th annual meeting of the International Scientifc Working Group on Tick-Borne Encephalitis (ISW-TBE). Ticks Tick Borne Dis. 2015; 6 (5): 545–8.

Rendi-Wagner P, Paulke-Korinek M, Kundi M, Wiedermann U, Laaber B, Kollaritsch H . Seroprotection 4 years following booster vaccination against tick-borne encephalitis. Int J Med Microbiol. 2008; 298 (1): 305-308

Published
2016-11-25
How to Cite
1.
Beškovnik L, Frelih T, Avšič Županc T, Korva M, Trop Skaza A. Immunogenicity of a booster vaccination against tick-borne encephalitis. TEST ZdravVestn [Internet]. 25Nov.2016 [cited 26Apr.2024];85(7-8). Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/1487
Issue
Vol 85 No 7-8 (2016): July-August
Section
Original article


The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.

The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory

The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.

The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.

The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.